Agendia NV (Agendia), a subsidiary of Agendia Inc, is a molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. The company discovers, develops and commercializes products for the treatment of cancer. Its products comprise mammaprint, blueprint, targetprint, coloprint, theraprint for breast cancer, theraprint for colon cancer, and symphony, and among others. Agendia product MammaPrint provides individualized metastasis risk assessment of breast cancer patients. The company collaborates with pharmaceutical companies, cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. It also has a presence in the US, Canada, Spain, Japan, Germany, Mexico, Korea and others. Agendia is headquartered in Amsterdam, Noord-Holland, the Netherlands.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Agendia NV
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Agendia NV Company Overview
- Agendia NV Company Snapshot
- Agendia NV Pipeline Products and Ongoing Clinical Trials Overview
- Agendia NV - Pipeline Analysis Overview
- Agendia NV - Key Facts
- Agendia NV - Major Products and Services
- Agendia NV Pipeline Products by Development Stage
- Agendia NV Ongoing Clinical Trials by Trial Status
- Agendia NV Pipeline Products Overview
- BluePrint 80-Gene Molecular Subtyping Assay
- BluePrint 80-Gene Molecular Subtyping Assay Product Overview
- BluePrint 80-Gene Molecular Subtyping Assay Clinical Trial
- MammaPrint 70-gene Breast Cancer Recurrence Assay
- MammaPrint 70-gene Breast Cancer Recurrence Assay Product Overview
- MammaPrint 70-gene Breast Cancer Recurrence Assay Clinical Trial
- Treatment Planning Digital Test - Breast Cancer
- Treatment Planning Digital Test - Breast Cancer Product Overview
- Tumor Cell Percentage Panel
- Tumor Cell Percentage Panel Product Overview
- Agendia NV - Key Competitors
- Agendia NV - Key Employees
- Agendia NV - Locations And Subsidiaries
- Head Office
- Recent Developments
- Agendia NV, Recent Developments
- Mar 20, 2024: Agendia Announces new Data from I-SPY 2 Showcasing Ability of new Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
- Mar 08, 2024: Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint + BluePrint’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
- Feb 01, 2024: Agendia Announces First Patient Enrolled in DEBRA Trial Using Mammaprint
- Sep 28, 2023: New Neoadjuvant Trial Confirms the Predictive Utility of Mammaprint + Blueprint
- May 31, 2023: Agendia studies reveal the influence of race on a tumor’s biology, reinforcing its commitment to advancing research of racial disparities in breast cancer
- May 31, 2023: Agendia research shows highest risk mammaprint category predicts strongest chemosensitivity in women with early-stage HR+HER2 - Breast Cancer
- Feb 13, 2023: Updated NCCN Guidelines Recognize MammaPrint UltraLow Risk result, highlighting its clinical utility for women with early-stage breast cancer who can safely forgo toxic treatments with excellent survival rates
- Dec 08, 2022: Agendia Level 1B evidence shows MammaPrint is the first and only FDA-cleared gene expression profiling test to predict benefit from extended endocrine therapy in early-stage breast cancer patients
- Dec 05, 2022: Agendia spotlights the future of personalized breast cancer care at 2022 San Antonio Breast Cancer Symposium
- Jun 05, 2022: Agendia presents data from the FLEX real world evidence trial in seven posters at ASCO 2022, showcasing the power of Its 30,000-patient breast cancer genome project
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Agendia NV Pipeline Products and Ongoing Clinical Trials Overview
- Agendia NV Pipeline Products by Equipment Type
- Agendia NV Pipeline Products by Indication
- Agendia NV Ongoing Clinical Trials by Trial Status
- Agendia NV, Key Facts
- Agendia NV, Major Products and Services
- Agendia NV Number of Pipeline Products by Development Stage
- Agendia NV Pipeline Products Summary by Development Stage
- Agendia NV Ongoing Clinical Trials by Trial Status
- Agendia NV Ongoing Clinical Trials Summary
- BluePrint 80-Gene Molecular Subtyping Assay - Product Status
- BluePrint 80-Gene Molecular Subtyping Assay - Product Description
- BluePrint 80-Gene Molecular Subtyping Assay - A Study to Evaluate the Addition of Precision to 2018 ASCO/CAP HER2 Testing Guidelines in Breast Cancer with Genomic Profiling
- BluePrint 80-Gene Molecular Subtyping Assay - MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
- BluePrint 80-Gene Molecular Subtyping Assay - Study to Assess the 12-chemokine Gene Expression Score in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
- BluePrint 80-Gene Molecular Subtyping Assay - Study to Evaluate the High Risk Breast Cancer Genes at 8q22-24 and Their Role in Patients by Using MammaPrint Risk of Recurrence Assay
- MammaPrint 70-gene Breast Cancer Recurrence Assay - Product Status
- MammaPrint 70-gene Breast Cancer Recurrence Assay - Product Description
- MammaPrint 70-gene Breast Cancer Recurrence Assay - A Study to Evaluate the Addition of Precision to 2018 ASCO/CAP HER2 Testing Guidelines in Breast Cancer with Genomic Profiling
- MammaPrint 70-gene Breast Cancer Recurrence Assay - I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And Molecular Analysis 2)
- MammaPrint 70-gene Breast Cancer Recurrence Assay - MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
- MammaPrint 70-gene Breast Cancer Recurrence Assay - Multi-institutional Study to Increase Breast Conserving Surgery (BCS) Rate with Personalized Neoadjuvant Strategy in ER Positive and HER2 Negative Breast Cancer Patients for whom BCS is not Feasible
- MammaPrint 70-gene Breast Cancer Recurrence Assay - Study to Assess the 12-chemokine Gene Expression Score in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
- MammaPrint 70-gene Breast Cancer Recurrence Assay - Study to Evaluate the High Risk Breast Cancer Genes at 8q22-24 and Their Role in Patients by Using MammaPrint Risk of Recurrence Assay
- Treatment Planning Digital Test - Breast Cancer - Product Status
- Treatment Planning Digital Test - Breast Cancer - Product Description
- Tumor Cell Percentage Panel - Product Status
- Tumor Cell Percentage Panel - Product Description
- Agendia NV, Key Employees
- Glossary
- Agendia NV Pipeline Products by Equipment Type
- Agendia NV Pipeline Products by Development Stage
- Agendia NV Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Nordic-MUbio BV
- Westburg BV
- DC Prime BV
- Affidea BV
